Titan Biotech Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹335.4
- Today's High:
- ₹354.7
- Open Price:
- ₹354.7
- 52W Low:
- ₹193.1
- 52W High:
- ₹458.9
- Prev. Close:
- ₹353.05
- Volume:
- 16276
Company Statistics
- Market Cap.:
- ₹1.47 billion
- Book Value:
- 70.53
- Revenue TTM:
- ₹1.11 billion
- Operating Margin TTM:
- 30.31%
- Gross Profit TTM:
- ₹400.93 million
- Profit Margin:
- 21.31%
- Return on Assets TTM:
- 25.24%
- Return on Equity TTM:
- 49.46%
Company Profile
Titan Biotech Limited had its IPO on under the ticker symbol 524717.
The company operates in the Other sector and Other industry. Titan Biotech Limited has a staff strength of 0 employees.
Stock update
Shares of Titan Biotech Limited opened at ₹354.7 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹335.4 - ₹354.7, and closed at ₹340.15.
This is a -3.65% slip from the previous day's closing price.
A total volume of 16,276 shares were traded at the close of the day’s session.
In the last one week, shares of Titan Biotech Limited have slipped by -9.22%.
Titan Biotech Limited's Key Ratios
Titan Biotech Limited has a market cap of ₹1.47 billion, indicating a price to book ratio of 1.8854 and a price to sales ratio of 0.9912.
In the last 12-months Titan Biotech Limited’s revenue was ₹1.11 billion with a gross profit of ₹400.93 million and an EBITDA of ₹355.18 million. The EBITDA ratio measures Titan Biotech Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Titan Biotech Limited’s operating margin was 30.31% while its return on assets stood at 25.24% with a return of equity of 49.46%.
In Q3, Titan Biotech Limited’s quarterly earnings growth was a positive 407% while revenue growth was a positive 76.5%.
Titan Biotech Limited’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 4.6521
- PEG
Its diluted EPS in the last 12-months stands at ₹28.603 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Titan Biotech Limited’s profitability.
Titan Biotech Limited stock is trading at a EV to sales ratio of 1.0872 and a EV to EBITDA ratio of 3.3329. Its price to sales ratio in the trailing 12-months stood at 0.9912.
Titan Biotech Limited stock pays annual dividends of ₹1 per share, indicating a yield of 0.79% and a payout ratio of 3.5%.
Balance sheet and cash flow metrics
- Total Assets
- ₹1.35 billion
- Total Liabilities
- ₹203.51 million
- Operating Cash Flow
- ₹-207251000.00
- Capital Expenditure
- ₹204.60 million
- Dividend Payout Ratio
- 3.5%
Titan Biotech Limited ended 2024 with ₹1.35 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹1.35 billion while shareholder equity stood at ₹1.10 billion.
Titan Biotech Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹203.51 million in other current liabilities, 82637000.00 in common stock, ₹1.02 billion in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹0 and cash and short-term investments were ₹48.64 million. The company’s total short-term debt was ₹66,996,000 while long-term debt stood at ₹2.99 million.
Titan Biotech Limited’s total current assets stands at ₹683.06 million while long-term investments were ₹0 and short-term investments were ₹0. Its net receivables were ₹210.08 million compared to accounts payable of ₹0 and inventory worth ₹361.70 million.
In 2024, Titan Biotech Limited's operating cash flow was ₹-207251000.00 while its capital expenditure stood at ₹204.60 million.
Comparatively, Titan Biotech Limited paid ₹0.04 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹340.15
- 52-Week High
- ₹458.9
- 52-Week Low
- ₹193.1
- Analyst Target Price
- ₹
Titan Biotech Limited stock is currently trading at ₹340.15 per share. It touched a 52-week high of ₹458.9 and a 52-week low of ₹458.9. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹319.2 and 200-day moving average was ₹271.85 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 6543.9% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Titan Biotech Limited
Similar Industry Stocks (Other)
Most Active
Top Gainers
Top Losers
About
Titan Biotech Limited manufactures and sells biological products in India. The company offers food ingredients, including hydrolyzed vegetable protein, yeast extract powder, calcium propionate powder, potassium sorbate, and calcium lactate; collagen and protein products, such as specter whey protein, collagen peptides, brown rice protein, fish collagen, pea protein isolate, chicken protein isolate, soya protein isolate, milk protein, and protein hydrolysate; and nutraceutical and pharmaceutical products comprising sodium caseinate, chondroitin sulfate, hyaluronic acid, methyl sulphonyl methane, chelated minerals, peptone, OX bile extract, cholic acid, cerebroprotein hydrolysate, methyl sulphonyl methane, iron protein succinylate, medicinal yeast, and brewer yeast protein, as well as liver, meat, malt, and yeast extracts. In addition, it provides products in the areas of animal nutrition, including binding agents, chelates minerals, mold inhibitors, proteins, and yeasts. The company’s products are used in the field of pharmaceuticals, nutraceuticals, food and beverages, biotechnology and fermentation, cosmetics, veterinary and animal feed, agriculture, microbiology culture media, plant tissue culture media, etc. The company also exports its products. Titan Biotech Limited was incorporated in 1992 and is based in New Delhi, India.